Americas to Dominate Biologics Market


Market Analysis 

The global biologics market is anticipated to touch USD 285,520.4 million at a 6.95% CAGR between 2018-2023, states the new Market Research Future (MRFR) report. Biologics, simply put, are made from materials that come from various living organisms such as animals, humans, and microorganisms, namely yeast or bacteria. Usually, biological products are manufactured, utilizing biotechnology methods or other advanced technologies. They are widely used for providing effective treatment for several complex diseases, including Crohn’s disease, psoriasis, and rheumatoid arthritis, which have limited options for treatment. Biologics is transforming the manner in which physicians treat common conditions that have plagued people for years. They have many potential benefits as; theoretically, they can be customized for hitting particular gene targets in the body. 

Numerous factors are propelling the Biologics Market. Such factors, as per the new Market Research Future report, include unremitting research & development activities, rising regulatory convergence, increasing government initiatives in the healthcare sector, growing demand as well as higher acceptability of innovative therapies, and the emergence of orphan drugs and personalized medicines. Additional factors propelling the growth of the biologics market include improvement in the healthcare infrastructure, rapid urbanization, increasing awareness about the efficacy and performance of biologics, and increasing prevalence of different chronic diseases. 

On the contrary, stringent government regulations, higher supervision, the rise of biosimilars, pricing pressures coming from regulators, difficulty to manufacture biologics, and side effects such as breathing problems, chest pain, change in blood pressure, and gastrointestinal complications are factors that may hamper the biologics market growth during the forecast period. 

Market Segmentation 

The Market Research Future report offers a complete segmental analysis of the biologics market based on manufacturing, disease indication, and product. 

Based on product, the global biologics market is segmented into gene therapy, growth factors, vaccines, interleukins, monoclonal antibody, and others. Of these, the monoclonal antibody segment will have the largest share in the market during the forecast period for its increasing use for enhancing the body’s immunity system. 

Based on disease indication, the biologics market is segmented into diabetes, cancer, psoriasis/psoriatic arthritis, rheumatoid arthritis, and others. Of these, the cancer segment dominated the market in 2018, but rheumatoid arthritis is predicted to dominate the biologics market over the forecast period for the rapid approval of different drugs by the regulatory agencies. 

Based on manufacturing, the biologics market is segmented into outsourced and in-house. Of these, the outsourced segment will have the maximum share in the market during the forecast period for the presence of several pharmaceutical companies, especially in developing countries. 

Regional Analysis

By region, the biologics market report covers the latest trends and growth opportunities across the Americas, the Asia Pacific, Europe, and the Middle East and Africa. Of these, the Americas will dominate the market during the forecast period. Various factors are propelling the growth of the biologics market in the region, such as investments in new facilities for producing drugs for clinical trials, strong economic growth of Canada and the US, and rapid adoption of manufacturing technologies. It is predicted to touch USD 129,652.7 million at a 4.31% CAGR.

The biologics market in the APAC region will grow at the fastest pace during the forecast period. Various factors are propelling the growth of the biologics market in the region, such as the changing healthcare sector, increasing geriatric populace, and the presence of different contract manufacturing organizations (CMOs) in the region. India is a major contributor in this region for its massive strides in biologics manufacturing.

Key Players 

Notable players profiled in the biologics market report include GlaxoSmithKline Plc (UK), Eli Lilly and Company (US), Bayer AG (Germany), Sanofi (France), F. Hoffman-La Roche AG (Switzerland), Novartis AG (Switzerland), Amgen (US), Pfizer Inc. (US), AstraZeneca (UK), and AbbVie, Inc. (US). Key players have incorporated specific strategies to increase their market share, such as acquisitions, expansions, and new product launches. 

Industry News

December 2019: Researchers at the Shenzhen Institutes of Advanced Technology, China, and Duke University, US, have created a platform that will make the biologics production process simpler. 


Comments

Post a Comment

Popular posts from this blog

Proteomics Market Analysis, Demand Overview, Growth Analysis, Current Trends, Updates, and Global Industry Forecast to 2023

Market Highlights: The global proteomics market is anticipated to hold a market value of USD 23.2 billion in the year 2017 and is expected to grow at a CAGR of 14.1% during the forecast period. Proteomics is a science which is used to estimate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. Also, it has extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis. Increasing need for personalized medicine, R&D expenditure, technological advancements and increased funding for proteomics project are expected to drive the market growth over the forecast period. For instance, in July 2017, Biognosys AG received USD 5 million funding from its new as well as existing investors. These new funds will be used for extending commercial operations and also to accelerate the development of next generation prote...
Read more

Pancreatic Cancer Market: America to Command the Largest Share

Market Overview: Pancreatic cancer can be defined as an enlarged tumor, which is generally caused by malignant cells present in the tissues of the pancreas. This type of cancer is generally caused due to drinking alcohol, smoking, genetic factors, radiotherapy in the past, obesity, inflammation of the pancreas, and diabetes mellitus. It is a type of cancer that starts in the pancreas and is a highly lethal disease. The global Pancreatic Cancer Market , as per a report by Market Research Future (MRFR) is touted to register 8.1% CAGR during the forecast period ( 2017-2023 ). The dearth of therapeutic approaches for early-stage detection has resulted in increased incidences of pancreatic cancer. Soaring prevalence of pancreatic cancer has resulted in germline mutations, thereby causing the defective genes to pass down to the children from their parents, thus making early detection of pancreatic cancer important. This has led to the growth of the market across the globe. Surging dem...
Read more

Immune Thrombocytopenia (ITP) Market is Estimated to Record Promising CAGR of 5.78% During Forecast 2018-2023

Market Highlights: As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers. ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ...
Read more